P-glycoprotein Structure and Evolutionary Homologies
Overview
Authors
Affiliations
Analysis of multidrug resistant cell lines has led to the identification of the P-glycoprotein multigene family. Two of the three classes of mammalian P-glycoproteins have the ability to confer cellular resistance to a broad range of structurally and functionally diverse cytotoxic agents. P-glycoproteins are integral membrane glycoproteins comprised of two similar halves, each consisting of six membrane spanning domains followed by a cytoplasmic domain which includes a nucleotide binding fold. The P-glycoprotein is a member of a large superfamily of transport proteins which utilize ATP to translocate a wide range of substrates across biological membranes. This superfamily includes transport complexes comprised of multicomponent systems, half P-glycoproteins and P-glycoprotein-like homologs which appear to require 12 alpha-helical transmembrane domains and two nucleotide binding folds for substrate transport. P-glycoprotein homologs have been isolated and characterized from a wide range of species. Amino acid sequences, the similarities between the halves and intron/exon boundaries have been compared to understand the evolutionary origins of the P-glycoprotein.
Jmel H, Romdhane L, Ben Halima Y, Hechmi M, Naouali C, Dallali H PLoS One. 2018; 13(4):e0194842.
PMID: 29652911 PMC: 5898725. DOI: 10.1371/journal.pone.0194842.
Li A, Song J, Lai Q, Liu B, Wang H, Xu Y Int J Exp Pathol. 2016; 97(6):412-421.
PMID: 27995666 PMC: 5370221. DOI: 10.1111/iep.12212.
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics.
Lin G, Mi P, Chu C, Zhang J, Liu G Adv Sci (Weinh). 2016; 3(11):1600134.
PMID: 27980988 PMC: 5102675. DOI: 10.1002/advs.201600134.
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).
Hodges L, Markova S, Chinn L, Gow J, Kroetz D, Klein T Pharmacogenet Genomics. 2010; 21(3):152-61.
PMID: 20216335 PMC: 3098758. DOI: 10.1097/FPC.0b013e3283385a1c.
Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.
Byrne D, Daly C, Nicamhlaoibh R, Howlett A, Scanlon K, Clynes M Cytotechnology. 2008; 27(1-3):113-36.
PMID: 19002787 PMC: 3449559. DOI: 10.1023/A:1008052401952.